Anmelden Kostenlos registrieren

Last updated: 4 July 2020 at 1:03pm EST

Berndt Modig Net Worth



Mr. Modig AXGT stock SEC Form 4 insiders trading

Berndt has made over 2 trades of the Axovant Gene Therapies stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 77,914 units of AXGT stock worth $70,123 on 29 December 2017.

The largest trade he's ever made was exercising 77,914 units of Axovant Gene Therapies stock on 29 December 2017 worth over $70,123. On average, Berndt trades about 17,314 units every 0 days since 2016. As of 29 December 2017 he still owns at least 77,914 units of Axovant Gene Therapies stock.

You can see the complete history of Mr. Modig stock trades at the bottom of the page.





Berndt Modig biography

Berndt Modig CPA serves as Independent Director of the Company. Since March 2016, Mr. Modig has served as Chief Executive Officer of Pharvaris B.V., a pre-clinical stage biotechnology company focusing on rare diseases. He served as Chief Financial Officer of Prosensa Holding N.V., a pharmaceutical company, from March 2010 until its acquisition by BioMarin Pharmaceutical Inc. in January 2015. From October 2003 to November 2008, Mr. Modig was Chief Financial Officer at Jerini AG, a pharmaceutical company, where he directed private financing rounds, its initial public offering in 2005, and its acquisition by Shire plc, a biopharmaceutical company acquired by Takeda Pharmaceutical Company, in 2008. Before that, Mr. Modig served as Chief Financial Officer at Surplex AG, a reseller of used industrial equipment, from 2001 to 2003, and as Finance Director Europe of U.S.-based Hayward Industrial Products Inc., a thermoplastic valve manufacturer, from 1999 to 2001. In previous positions, Mr. Modig was a partner in the Brussels-based private equity firm Agra Industria from 1994 to 1999 and a Senior Manager in the Financial Services Industry Group of Price Waterhouse LLP in New York from 1991 to 1994. Mr. Modig currently serves as a director and the chair of the audit committee of Kiadis Pharma N.V., a public biopharmaceutical company. He also serves as chair of the audit committee and as a director of Centogene N.V., a public biopharmaceutical company. He also previously served on (i) the board of directors of Auris Medical Holding Ltd., a pharmaceutical company, from April 2014 to March 2018, and (ii) the board of directors of Affimed N.V, a public biopharmaceutical company, from September 2014 to August 2020. Mr. Modig received his bachelor’s degree in business administration, economics and German from the University of Lund, Sweden and his M.B.A. from INSEAD, Fontainebleau, France and is a Certified Public Accountant (inactive). Modig’s extensive international experience in finance and operations,

What is the salary of Berndt Modig?

As the Independent Director of Axovant Gene Therapies, the total compensation of Berndt Modig at Axovant Gene Therapies is $232,474. There are 5 executives at Axovant Gene Therapies getting paid more, with Pavan Cheruvu having the highest compensation of $2,868,750.



How old is Berndt Modig?

Berndt Modig is 61, he's been the Independent Director of Axovant Gene Therapies since 2015. There are 2 older and 6 younger executives at Axovant Gene Therapies. The oldest executive at Axovant Gene Therapies Ltd. is Atul Pande, 66, who is the Lead Independent Director.

What's Berndt Modig's mailing address?

Berndt's mailing address filed with the SEC is 5, 320 W 37th St, New York, NY 10018, USA.

Insiders trading at Axovant Gene Therapies

Over the last 6 years, insiders at Axovant Gene Therapies have traded over $0 worth of Axovant Gene Therapies stock and bought 5,401,703 units worth $20,204,515 . The most active insiders traders include Sciences Ltd. Roivant, Andrew Lo und Associates Gp Llcqvt Financ.... On average, Axovant Gene Therapies executives and independent directors trade stock every 65 days with the average trade being worth of $1,890,596. The most recent stock trade was executed by Atul Pande on 8 July 2020, trading 10,000 units of AXGT stock currently worth $27,300.



What does Axovant Gene Therapies do?

Axovant Gene Therapies Ltd., a clinical-stage company, develops gene therapies for neurodegenerative diseases. The company's product pipeline includes AXO-Lenti-PD program, an in vivo lentiviral gene therapy for the treatment of Parkinson's disease, which is in Phase II clinical trials; the AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis is in Phase I/II clinical trials; and the AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis that is in Phase I/II clinical trials. It has a license agreement with Oxford BioMedica (UK) Ltd.; license and collaboration agreement with Benitec Biopharma Limited; exclusive license agreement with The University of Massachusetts Medical School; and collaboration agreement with Invitae Corporation. The company was formerly known as Axovant Sciences Ltd. The company was founded in 2014 and is based in London, the United Kingdom.



What does Axovant Gene Therapies's logo look like?

Axovant Gene Therapies Ltd. logo

Axovant Gene Therapies executives and stock owners

Axovant Gene Therapies executives and other stock owners filed with the SEC include: